Status | Study |
Recruiting |
Study Name: Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions Condition: Solid Tumors CNS Tumors Neuroblastoma Date: 2016-01-04 Interventions: Drug: Entrectinib TRKA/B/C, ROS1, and ALK inhibitor |
Recruiting |
Study Name: Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors Condition: Neoplasms Central Nervous System Neoplasms Date: 2015-12-10 Interventions: Drug: LOXO-101 (larotrectinib) Capsules / Liquid Administration |
Withdrawn |
Study Name: Studying Biomarkers in Samples From Younger Patients With Kidney Cancer Condition: Clear Cell Renal Cell Carcinoma Congenital Mesoblastic Nephroma Date: 2012-07-15 Interventions: Other: laboratory biomarker analysis Correlative studies |
Recruiting |
Study Name: Study of Kidney Tumors in Younger Patients Condition: Clear Cell Sarcoma of the Kidney Congenital Mesoblastic Nephroma Date: 2009-05-09 Interventions: Other: laboratory biomarker analysis |
Active, not recruiting |
Study Name: Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Condition: Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Date: 2008-11-07 Interventions: Drug: carboplatin Drug: dasatinib |
Active, not recruiting |
Study Name: Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Condition: Bladder Cancer Brain and Central Nervous System Tumors Eso Date: 2008-09-22 Interventions: Genetic: DNA analysis Genetic: polymorphis |
Completed |
Study Name: Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Condition: Cancer Date: 2007-10-01 Interventions: Drug: Fentanyl sublingual spray |